Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 23;13:4264. doi: 10.1038/s41467-022-31780-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Variants were assigned to different levels of clinical actionability according to OncoKB. The distribution of the highest level of actionable variants across all patients was shown in the pie chart. The colors representing each level were used throughout the other panels in this figure. b Distribution of highest level of actionable variants across tumor types. c Details of the 30 most common actionable variants, proportions of levels in corresponding tumor types, and their potential sensitive drugs. The numbers of patients in each level were shown in the bar graph. The right table showed genes, variants, and the tumor type for each level of clinical actionability, as well as the proportion of patients in the corresponding tumor type and level. Potential sensitive drugs suggested by biomarkers were also shown in the table.